research report · KYTX

Kyverna Therapeutics, Inc.

Johannes Vermeer, Woman Holding a Balance, c. 1664, detail · National Gallery of Art

Viridis’s deep research report, written Nov 14, 2026 from its quarterly report (10-Q for the quarter ended Sep 30, 2026, filed Nov 12, 2026). Written and checked with Anthropic’s Claude models.

your email, no card; what you get

business trajectory

Improving

better on balance: sales, margins, cash or competitive position

financial resilience

Fragile

needs money within two years that it has not secured

Judgments of the business from its filings, not of its shares: no valuation, no advice.

bottom line

Kyverna's lead cell therapy, miv-cel, is a stronger asset than three months ago. The company completed its stiff person syndrome (SPS) marketing application, a Biologics License Application (BLA), in the fourth quarter of 2026 and requested priority review. The application rests on one-year data showing a 49% median walking-speed improvement in 26 patients. The balance sheet moved the other way: cash and securities fell to $170.6M at September 30, 2026, from $279.3M at year-end, and the company's "runway into 2028" now counts undrawn loans while launch hiring pushes costs up. On balance the business is improving through regulatory progress, but its plan through launch is not funded, and new capital in 2027 looks likely (my inference).

what changed this quarter

  • The Q3 2026 net loss was $41.9M, against $36.8M a year earlier. Research and development (R&D) fell 11% to $27.0M; general and administrative costs (G&A) rose 92% to $15.9M.
  • Cash and securities stood at $170.6M at September 30, down $28.8M from June 30. Q3 operating cash use was $35.4M (derived).
  • The BLA was completed in Q4 2026 with priority review requested under the Regenerative Medicine Advanced Therapy (RMAT) designation. The 10-K had planned the submission for the first half of 2026.
  • On October 20 the court refused to dismiss the IPO-related Section 11 and 15 claims.
  • The KYV-102 manufacturing program was deprioritized. In August miv-cel received an RMAT designation in non-active secondary progressive multiple sclerosis.

in the full report

Its findings, each with the evidence, the strongest counterpoint and what would prove it wrong:

  • The SPS filing is complete, but it rests on durable data from a small trial without a control group
  • Reaching 2028 needs the loan and a burn no higher than Q3's
  • Launch spending is rising; the lower Q3 burn reflects payment timing
  • The IPO lawsuit is now an open, unquantified liability

Then its finances, the quality of its earnings, its management, the case for and against, and what to watch, its claims cited to the filings and checked against them.

read it whole

Your email and the code we send it, no card. The report then opens: a free account has 2 free reports a month from the library, the reports already written. Already have a Viridis account? Use its email, and the report goes on it. You also see what KYTX files, free: its deadlines and its red flags.

Subscribe: your plan’s reports work on any company that files with the SEC, written for you if nobody has asked yet, and each new one on the companies you choose comes as they file.

In Claude or ChatGPT, ask: “What does Viridis's report on KYTX say?” Add Viridis to Claude, or to ChatGPT.